Pharming Group (OTCMKTS:PHGUF – Get Free Report) is projected to issue its results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of $0.0015 per share and revenue of $89.7220 million for the quarter.
Pharming Group Price Performance
Shares of OTCMKTS PHGUF opened at $1.51 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.16 and a quick ratio of 2.39. The company’s 50-day moving average price is $1.78 and its 200 day moving average price is $1.62. Pharming Group has a 52 week low of $0.79 and a 52 week high of $2.17.
Pharming Group Company Profile
Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.
Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.
See Also
- Five stocks we like better than Pharming Group
- The gold chart Wall Street is terrified of…
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
